公开(公告)号：US10039820B2

公开(公告)日：2018-08-07

申请号：US15331596

申请日：2016-10-21

Applicant: HAWAII BIOTECH, INC.

Inventor： Beth-Ann Coller ,  Vidya Pai ,  Carolyn L. Weeks-Levy ,  Steven A. Ogata

IPC: A61K39/12 ,  A61K39/00

Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.

公开(公告)号：US20170165349A1

公开(公告)日：2017-06-15

申请号：US15331596

申请日：2016-10-21

Applicant: HAWAII BIOTECH, INC.

Inventor： Beth-Ann Coller ,  Vidya Pai ,  Carolyn L. Weeks-Levy ,  Steven A. Ogata

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N2770/24134 ,  C12N2770/24171 ,  Y02A50/394

Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.